Syntara Secures FDA Backing for Myelofibrosis Trial and Raises A$8 Million

What happened

In late April 2026, Syntara reported FDA support via a Type C meeting for a ~100-patient, placebo-controlled Phase 2b trial of amsulostat in myelofibrosis. On 29 April 2026, the company announced a placement raising about A$8 million across two tranches to fund the programme.

Why it matters

FDA support reduces regulatory uncertainty for the small biotech and improves odds of a pharmaceutical partnership. The capital raise is essential as Syntara is pre-revenue and clinical trials are expensive. The therapy addresses unmet needs by improving symptoms and reducing spleen size in myelofibrosis.